birinapant

02/08/2016 - "Birinapant is a smac-mimetic (SM) in clinical trials for treating cancer. "
11/01/2015 - "These results support the ongoing clinical trials of birinapant in patients with cancer."
04/01/2022 - "Compared with CDDP monotherapy, birinapant combined with CDDP showed better inhibition of tumor growth (P=0.121). "
04/01/2022 - "Huh6 cells were exposed to CDDP and/or birinapant in order to confirm tumor growth inhibition. "
04/01/2022 - "A WST‑8 assay was performed to evaluate the tumor growth inhibitory effect of birinapant on the human HB cell lines, Huh6 and HepG2. "

04/01/2013 - "Birinapant in combination with TNF-α is effective in a melanoma cell line with acquired resistance to BRAF inhibitors."
01/01/2020 - "Applied to expression data of a cohort of n = 365 metastatic melanoma patients in a proof of concept in silico trial, the predictor suggested that IZI1551/Birinapant responsiveness could be expected for up to 30% of patient tumours. "
01/01/2020 - "Across a panel of 16 melanoma cell lines, responsiveness to IZI1551/Birinapant was heterogeneous, with complete resistance and pronounced synergies observed. "
01/01/2020 - "Here, we demonstrate that a novel and translationally relevant hexavalent TRAIL receptor agonist, IZI1551, in combination with Birinapant, a clinically tested IAP antagonist, efficiently induces cell death in various melanoma models, and that responsiveness can be predicted by combining pathway analysis, data-driven modelling and pattern recognition. "
06/01/2019 - "We also found that the bivalent IAP antagonist birinapant significantly reduced the invasive capability of melanoma cells. "

12/10/2020 - "Taken together, our results indicate that a combination of birinapant and TRAIL may be a promising treatment for TRAIL-resistant breast cancer."
10/01/2020 - "Here we have evaluated the efficacy of the preclinical Smac-mimetic compound A and the clinical lead birinapant on breast cancer cells. "
04/18/2017 - "NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP."
01/01/2022 - "Birinapant further enhances the cytotoxic effect of chemotherapies and targeted therapies used in the treatment of ER+ breast cancer models selectively in the RB-deficient setting. "
10/01/2020 - "Taken together, our findings provide a rationale for prospectively selecting patients whose breast tumors contain a competent death receptor signaling pathway for the further evaluation of birinapant in the clinic."

12/15/2020 - "Despite on-target activity, however, pre-clinical trials of single-agent birinapant have exhibited minimal activity in the recurrent ovarian cancer setting. "
02/18/2023 - "We previously conducted a phase 2 clinical trial of the single-agent SMAC mimetic birinapant and observed minimal drug response in women with recurrent ovarian cancer despite demonstrating on-target activity. "
12/15/2020 - "These findings provide a rationale for the integration of birinapant and docetaxel in a phase 2 clinical trial for recurrent ovarian cancer where treatment options are often limited and minimally effective."
03/01/2022 - "Findings from the in vitro studies demonstrated that the birinapant and carboplatin combination was effective in targeting a subset of ovarian cancer cell lines and platinum‑resistant primary patient tumor samples. "
02/15/2016 - "It was hypothesized that blocking IAPs with birinapant would increase tumor cell death and result in objective responses for women with platinum-refractory and -resistant ovarian cancer. "

01/01/2018 - "In this study, liquid chromatography-mass spectrometry-based proteomic analysis was applied to characterize the combination of gemcitabine and birinapant in pancreatic cancer cells, which was shown previously to be synergistic. "
10/23/2020 - "Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells."
10/01/2018 - "Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts."
01/01/2018 - "Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar)."
01/01/2018 - "Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells."